Creating new compounds to study bacterial sugar metabolism and develop anti-parasitic treatments
Chemical synthesis to access rare heterocycles and tool compounds to probe bacterial polysaccharide metabolism
This study is looking at new ways to make special nitrogen-rich compounds that might help fight infections and other health issues, and it could lead to better treatments for patients dealing with bacterial problems or autoimmune diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clemson University NIH-funded |
| Lab location | 1 site (Clemson, United States) |
| Project ID | NIH-10841815 on NIH RePORTER |
What this research studies
This research focuses on developing new synthetic methods to create rare nitrogen-rich compounds that could be used in medicine. By synthesizing a unique compound known as diazacyclobutene (DCB), the researchers aim to explore its potential anti-parasitic properties and other biological activities. Additionally, the study will investigate how gut bacteria metabolize polysaccharides, which could lead to new insights into bacterial infections and autoimmune diseases. Patients may benefit from the findings as they could lead to new treatments for various conditions related to bacterial metabolism and infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from bacterial infections, autoimmune diseases, or those who may benefit from new anti-parasitic agents.
Not a fit: Patients with conditions unrelated to bacterial infections or parasitic diseases may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments for bacterial infections and parasitic diseases.
How similar studies have performed: Previous research has shown promise in developing new compounds for treating bacterial infections and parasitic diseases, indicating that this approach could yield significant results.
Where this research is happening
Clemson, United States
- Clemson University — Clemson, United States (Active)
Researchers
- Principal investigator: Whitehead, Daniel Charles — Clemson University
- Study coordinator: Whitehead, Daniel Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.